Subscribe to RSS
DOI: 10.1055/s-2008-1065365
© Georg Thieme Verlag KG Stuttgart · New York
Blood Coagulation, Fibrinolysis and Lipid Profile in Patients with Primary Hyperparathyroidism: Increased Plasma Factor VII and X Activities and D-Dimer Levels
Publication History
received 07.07.2007
first decision 15.01.2008
accepted 15.03.2008
Publication Date:
16 May 2008 (online)
Abstract
Background and Objectives: Primary hyperparathyroidism (PHPT) is associated with an increased cardiovascular mortality and morbidity rate. However, the exact role of PTH and/or calcium in the development of cardiovascular disease (CVD) is still controversial. The influence of PHPT on hemostasis is yet unknown. Therefore, the main purpose of this study was to investigate the markers of endogenous coagulation/fibrinolysis and to evaluate the relationships between these hemostatic parameters, serum lipid profile and serum calcium and PTH in patients with PHPT.
Design and Methods: Twenty-three patients with PHPT and 20 age-matched healthy controls were included in the study. Fibrinogen, factors V, VII, VIII, IX and X activities, von Willebrand factor (vWF), antithrombin III (AT III), protein C, protein S, tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor-1 (PAI-1), as well as common lipoprotein variables, were measured. The relationships between biochemical parameters and these hemostatic parameters were examinated.
Results: Compared with the control subjects, platelet count, FVII, FX activities, and D-Dimer levels were significantly increased in patients with PHPT (p<0.001, p<0.05, p<0.001, and p<0.05, respectively). Among the lipids, the levels of TC, TG and LDL-C were significantly increased in patients with PHPT (p<0.01, p<0.001, p<0.001, respectively) than those in controls. In patients with PHPT, we showed a positive correlation between urinary phosphorus excretion and factors VIII, IX, and X (r: 0.572, p<0.01; r: 0.543, p<0.01; r: 0.532, p<0.01, respectively). F IX activity was positively correlated with TC (r: 0.463, p<0.05) and LDL-C (r: 0.549, p<0.01) There was a positive correlation between serum ALP and PAI-1 levels (r: 0.451, p<0.05). ApoB was positively correlated with D-Dimer (r: 0.421, p<0.05). We did not find any significant correlation between iPTH and serum calcium and the hemostatic parameters that we measured.
Interpretation and Conclusions: In conclusion, we found some important differences in the hemostatic parameters between the patients with PHPT and healthy controls. Increased platelet count, F VII and FX activities and D-Dimer levels in patients with PHPT represent a potential hypercoagulable state, which might augment the risk for atherosclerotic and atherothrombotic complications. This condition may contribute to the excess mortality rate due to CVD in patients with PHPT.
Key words
coagulation - fibrinolysis - primary hyperparathyroidism - lipid profile
References
- 1 Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease–a review. Eur Heart J. 2004; 25 1776-1787
- 2 Hedback G, Oden A. Increased risk of death from primary hyperparathyroidism–an update. Eur J Clin Invest. 1998; 28 271-276
- 3 Kiernan TJ, O’Flynn AM, MacDermott JH, Kearney P. Primary hyperparathyroidism and the cardiovascular system. Int J Cardiol. 2006; 113 E89-E92
- 4 Rapado A. Arterial hypertension and primary hyperparathyroidism. Incidence and follow-up after parathyroidectomy. Am J Nephrol. 1986; 6 ((Suppl 1)) 49-50
- 5 Piovesan A, Molineri N, Casasso F, Emmolo I, Ugliengo G, Cesario F, Borretta G. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf). 1999; 50 321-328
- 6 Stefenelli T, Abela C, Frank H, Koller-Strametz J, Globits S, Bergler-Klein J, Niederle B. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab. 1997; 82 106-112
- 7 Baykan M, Erem C, Erdogan T, Hacihasanoglu A, Gedikli O, Kiris A, Kucukosmanoglu M, Ersoz HO, Celik S. Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism. Int J Cardiovasc Imaging. 2007; 23 323-328
- 8 Kosch M, Hausberg M, Vormbrock K, Kisters K, Rahn KH, Barenbrock M. Studies on flow-mediated vasodilation and intima-media thickness of the brachial artery in patients with primary hyperparathyroidism. Am J Hypertens. 2000; 13 759-764
- 9 Chadwick DR, Harrison BJ, Chan P, Chong L, Peachell P. Vasoactive and proliferative effects of parathyroid hormone and parathyroid hormone-related peptide on human vascular smooth muscle. Br J Surg. 2000; 87 1529-1533
- 10 Lind L, Ljunghall S. Serum calcium and the ECG in patients with primary hyperparathyroidism. J Electrocardiol. 1994; 27 99-103
- 11 Procopio M, Magro G, Cesario F, Piovesan A, Pia A, Molineri N, Borretta G. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med. 2002; 19 958-961
- 12 Hagstrom E, Lundgren E, Lithell H, Berglund L, Ljunghall S, Hellman P, Rastad J. Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: population-based study over five years. Clin Endocrinol (Oxf). 2002; 56 253-260
- 13 Grey AB, Evans MC, Stapleton JP, Reid IR. Body weight and bone mineral density in postmenopausal women with primary hyperparathyroidism. Ann Intern Med. 1994; 121 745-749
- 14 Westerdahl J, Valdemarsson S, Lindblom P, Bergenfelz A. Urate and arteriosclerosis in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2001; 54 805-811
- 15 Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O’Fallon WM, Melton LJ. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med. 1998; 104 115-122
- 16 Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone levels predict coronary heart disease: the Tromso Study. Eur J Cardiovasc Prev Rehabil. 2004; 11 69-74
- 17 Fallo F, Camporese G, Capitelli E, Andreozzi GM, Mantero F, Lumachi F. Ultrasound evaluation of carotide artery in primary hyperparathyroidism. J Clin Endocrinol Metab. 2003; 88 2096-2099
- 18 Lumachi E, Ermani M, Luisetto G, Nardi A, Basso SMM, Camozzi V, Favia G. Relationship between serum parathyroid hormone, serum calcium and arterial blood pressure in patients with primary hyperparathyroidism: results of a multivariate analysis. Eur J Endocrinol. 2002; 146 643-647
- 19 Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am J Epidemiol. 2006; 163 334-341
- 20 Haverkate F. Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vascul Pharmacol. 2002; 39 109-112
- 21 Fibrinogen Studies Collaboration. . Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil. 2004; 11 9-17
- 22 Danesh J, Whincup P, Walker M. et al . Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001; 103 2323-2327
- 23 Danesh J, Wheeler JG, Hirschfield GM. et al . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350 1387-1397
- 24 Lowe GD, Danesh J, Lewington S. et al . Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J. 2004; 25 252-259
- 25 Hueper W. Metastatic calcifications in the organs of the dog after injections of parathyroid extract. Arch Pathol. 1927; 3 14-25
- 26 Hilgard P, Hohage R, Schmitt W, Kohle W. Microangiopathic haemolytic anaemia associated with hypercalcaemia in an experimental rat tumour. Br J Haematol. 1973; 24 245-254
- 27 Hilgard P. Experimental hypercalcaemia and whole blood clotting. J Clin Pathol. 1973; 26 616-619
- 28 Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, Poletti E, Mecca G, Gaetano G de. Parathyroid hormone inhibits human platelet function. Lancet. 1981; 2 1321-1323
- 29 Leithner C, Kovarik J, Sinzinger H, Woloszczuk W. Parathyroid hormone does not inhibit platelet aggregation. Lancet. 1984; 1 367-368
- 30 Girolami A, Simioni P, Scarano L, Girolami B. Venous and arterial thrombophilia. Haematologica. 1997; 82 96-100
- 31 Silverberg SJ, Bilezikian JP. Cytokines in primary hyperparathyroidism–factors that matter. J Clin Endocrinol Metab. 1996; 81 3448-3449
- 32 Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001; 98 2720-2725
- 33 Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2005; 25 2043-2053
- 34 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR. et al . Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986; 2 533-537
- 35 Junker R, Heinrich J, Schulte H, Loo J van de, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol. 1997; 17 1539-1544
- 36 Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis. 1990; 85 169-173
- 37 Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: fatal and non-fatal events. QJM. 1994; 87 403-406
- 38 Heinrich J, Balleisen L, Schulte H, Assmann G, Loo J van de. Fibrinogen and factor VII in the prediction of coronary risk Results from the PROCAM study in healthy men. Arterioscler Thromb. 1994; 14 54-59
- 39 Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb. 1993; 13 1829-1836
- 40 Vaziri ND, Kennedy SC, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med. 1992; 93 651-657
- 41 Simpson HCR, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf N. Hypertriglycerideamia and hypercoagulability. Lancet. 1983; 1 786-790
- 42 Zitoun D, Bara L, Basdevant A, Samama MM. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler Thromb Vasc Biol. 1996; 16 77-81
- 43 Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP, Meade TW. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to aVIIa in hyperlipidaemia, with possible implications for ischaemic heart disease. Br J Haematol. 1985; 59 249-258
- 44 Sousa JC de, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol. 1988; 41 940-944
- 45 Negri M, Arigliano PL, Talamini G, Carlini S, Manzato F, Bonadonna G. Levels of plasma factor VII and factor VII activated forms as a function of plasma trigylceride levels. Atherosclerosis. 1993; 99 55-61
- 46 Hoffman CJ, Lawson WE, Miller RH, Hultin MB. Correlation of vitamin K-dependent clotting factors with cholesterol and trigylcerides in healthy young adults. Arterioscler Thromb. 1994; 14 1737-1740
- 47 Okura Y, Hayashi K, Shingu T, Kuga Y, Nomura S, Kajiyama G, Nakashima Y, Keijiro S. Angiotensin-converting enzyme insertion/deletion genotype is associated with the activities of plasma coagulation factor VII and X independent of triglyceride metabolism. Coranary Artery Dis. 2003; 14 285-291
- 48 Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA. 1992; 89 2317-2320
- 49 Koo BH, Chung KH, Hwang KC, Kim DS. Factor Xa induces mitogenesis of coronary artery smooth muscle cell via activation of PAR-2. FEBS Lett. 2002; 523 85-89
- 50 Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Voorhees L Van, Krone RJ, Bodenheimer MM, Hochman J, Dwyer Jr EM, Arora R, Marcus FI, Watelet LF, Case RB. Thrombo-genic factors and recurrent coronary events. Circulation. 1999; 99 2517-2522
- 51 Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res. 1994; 73 1-19
- 52 Tataru MC, Heinrich J, Junker R, Schulte H, Eckardstein A von, Assmann G, Koehler E. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J. 1999; 20 1493-1502 , . Comment in: Eur Heart J. 1999; 20: 1443–44.
- 53 Morishita E, Jokaji H, Matsuda T. Hyperlipidemia and hemostatic system. J Atheroscler Thromb. 1995; 2 ((Suppl 1)) S36-40
- 54 Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med. 1997; 126 638-644
- 55 Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasmin activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998; 98 2241-2247
- 56 Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resist-ance in metabolic disorders: the Bruneck Study. Diabetes. 1998; 47 1643-1649
- 57 Garcia de la Torre N, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer. 2003; 10 309-322
- 58 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report . National Cholesterol Education Program National Heart, Lung, and Blood Institute National Institutes of Health NIH Publication No. 02-5215. September 2002;
Correspondence
Prof. Dr. C. EremMD, PhD
K.T.Ü. Tıp Fakültesi
İç Hastalıkları Anabilim Dalı
61080
Trabzon
Turkey
Phone: +90/462/377 54 49
Fax: +90/462/325 22 70
Email: cihangirerem@hotmail.com
Email: cihangirerem@netscape.net